drugset / Trial / NCT06611904

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT06611904

Active not recruiting 60 enrolled Attikon Hospital
RandomizedSingle-groupOpen-labelPrevention

Summary

Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.

Timeline

Start
2018-02-01
Primary completion
2022-02-05
Completion
2024-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule
Comparator Dulaglutide Peptide